Azarga approved by EMEA
Azarga (brinzolamide 10mg/ml and timolol 5mg/ml fixed combination) has been approved by the European Medicines Agency (EMEA) for decreasing intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension after failure of monotherapy, according to an announcement from Alcon, Azarga's manufacturer.
Azarga (brinzolamide 10 mg/ml and timolol 5 mg/ml fixed combination) has been approved by the European Medicines Agency (EMEA) for decreasing intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension after failure of monotherapy, according to an announcement from Alcon, Azarga's manufacturer.
A clinical trial has demonstrated that Azarga is as safe as, but more effective than, either of its constituent components, brinzolamide and timolol. A separate study showed that Azarga is as safe as Cosopt (timolol/dorzolamide fixed combination; Merck), but is better tolerated and more comfortable for patients.
Azarga will be available in Europe from early next year.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
